Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Customer Center
Customer Center

Development and validation of a LC/MS/MS method for quantification of nobiliside A in rat plasma

2023-07-11
|
Page View:

27.jpgNobiliside A, a new triterpene glycoside, exhibits some biological activities including antifungal and cytotoxic effects. A LC/MS/MS method was developed and validated for determination of Nobiliside A in rat plasma, would prove to be useful for other pharmacokinetic assessments. Male SD rats were housed in Medicilon animal facility. The animal experiments of the present study were approved by IACUC of Medicilon and were carried out in accordance with the SOPs of the facility.

Reference:

Dan Guo, et al. Development and validation of a LC/MS/MS method for quantification of nobiliside A in rat plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jan 15;877(3):323-7. doi: 10.1016/j.jchromb.2008.12.007. 


Return
Relevant News
A new LC-MS/MS method for the simultaneous quantification of Dabrafenib and its main metabolite hydroxy-dabrafenib (OHD) in human plasma has been developed and validated
2023-07-11
Increased understanding of molecular pathways leads to the development of effective targeted therapies for the treatment of solid tumors. Dabrafenib (DAB) undergoes oxidative metabolism via cytochrome P450 (CYP) 3A4 and CYP2C8 to form hydroxy-dabrafenib (OHD), an active metabolite, with a twofold higher potency than an inhibitor of mutant BRAF. OHD (purity>99 %) was synthesized by Medicilon. Medicilon synthetic chemistry team is capable of the independent design of synthesis pathways and complex compound treatments, key to helping accelerate drug discovery.
ARD-2128 is a PROTAC AR degrader with excellent plasma and microsomal stability. The in vitro stability and PK studies were performed by Medicilon
2023-07-11
ARD-2128 is a bona fide PROTAC androgen receptor (AR) degrader and strongly suppresses AR-regulated genes in a dose- and time-dependent manner in AR+ prostate cancer cell lines. ARD-2128 has excellent plasma and microsomal stability in all the five species (Human, Mouse, Rat, Dog, and Monkey). The in vitro stability and pharmacokinetic (PK) studies were performed by Medicilon.
AD80 is a multi-kinase inhibitor with anti-tumoral activity across a variety of hepatocellular carcinoma preclinical models. Quantities of AD80 in blood plasma were determined by LC-MS/MS at Medicilon
2023-07-11
Liver cancer is the fourth greatest cause of cancer related mortality. AD80 is a multi-kinase inhibitor with anti-tumoral activity across a variety of hepatocellular carcinoma (HCC) preclinical models, including mouse xenografts. AD80 is highly active in a tumor xenograft model. Experimental dosing for AD80 was determined from maximum tolerated dosage (MTD) studies and pharmacokinetic (PK) analysis. Quantities of AD80 in blood plasma were determined by LC-MS/MS at Medicilon.